|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8207197||HARMONY||Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine|| |
(6 years from now)
|US8354430||HARMONY||Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine|| |
(2 years from now)
|US8486947||HARMONY||Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands|| |
(5 years from now)
Wakix is owned by Harmony.
Wakix contains Pitolisant Hydrochloride.
Wakix has a total of 3 drug patents out of which 0 drug patents have expired.
Wakix was authorised for market use on 14 August, 2019.
Wakix is available in tablet;oral dosage forms.
Wakix can be used as method of treating excessive daytime sleepiness in patients with narcolepsy; method of treating cataplexy in patients with narcolepsy.
Drug patent challenges can be filed against Wakix from 2023-08-15.
The generics of Wakix are possible to be released after 07 March, 2030.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Chemical Entity Exclusivity (NCE)||Aug 14, 2024|
|Orphan Drug Exclusivity (ODE)||Oct 13, 2027|
|New Indication (I)||Oct 13, 2023|
NCE-1 date: 2023-08-15
Market Authorisation Date: 14 August, 2019
Treatment: Method of treating excessive daytime sleepiness in patients with narcolepsy; Method of treating cataplexy in patients with narcolepsy
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic